bevacizumobia

Bevacizumab is a monoclonal antibody used in the treatment of various cancers. It is a humanized IgG1 kappa monoclonal antibody that targets vascular endothelial growth factor (VEGF), a protein that plays a crucial role in the formation of new blood vessels. By inhibiting VEGF, bevacizumab prevents the growth of new blood vessels that supply tumors with oxygen and nutrients, thereby slowing or stopping the growth of cancer cells.

Bevacizumab was approved by the U.S. Food and Drug Administration (FDA) in 2004 for the treatment of metastatic colorectal cancer. It has since been approved for use in other types of cancer, including glioblastoma, non-small cell lung cancer, and kidney cancer. The drug is administered via intravenous infusion.

Bevacizumab is typically used in combination with other chemotherapeutic agents or targeted therapies. The combination of bevacizumab with chemotherapy has been shown to improve overall survival and progression-free survival in patients with certain types of cancer.

The most common side effects of bevacizumab include hypertension, proteinuria, and bleeding. Serious side effects may include gastrointestinal perforation, stroke, and hemorrhage. As with any medication, bevacizumab should be used under the supervision of a healthcare provider.